Therapeutic choices in younger patients with chronic myelogenous leukemia.
BACKGROUND
Allogeneic stem cell transplantation (SCT) and interferon (IFN)-alpha therapy have significantly improved the prognosis of patients with Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Both therapies may be suitable for younger patients. The authors reviewed current data to assist in prioritizing these modalities in an individual patient.


METHODS
The authors reviewed and summarized current data on outcomes of SCT and IFN-alpha therapy in patients with early chronic phase CML.


RESULTS
Several disease-, patient-, and physician-related factors affect outcomes with both modalities. Interferon-alpha does not induce myelofibrosis. The course of CML is predictable in most patients; sudden emergence of blastic phase; disease is unusual. There is no significant adverse impact of delaying SCT for the 12 months usually necessary to assess cytogenetic response to an IFN-alpha-based regimen. Interferon-alpha may be discontinued some months before SCT and is not associated with an adverse impact on post-SCT outcomes.


CONCLUSIONS
An individualized risk assessment-based approach is of value in prioritizing SCT and IFN-alpha in younger patients with chronic phase CML. The authors recommend a risk-based therapy algorithm based on the expected SCT associated 1-year mortality for an individual patient.
Kantarjian
H M
HM
Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas, USA. hkantarj@mdanderson.org
Giles
F J
FJ
O'Brien
S
S
Giralt
S
S
Talpaz
M
M
D000328:Adult; D000367:Age Factors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000517:prevention & control; D015996:Survival Rate; D016896:Treatment Outcome
D016898:Interferon-alpha